Fair Value Measurements - Narrative (Detail) - USD ($) $ in Millions |
2 Months Ended | 4 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Dec. 31, 2021 |
Oct. 19, 2021 |
Dec. 31, 2022 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Nov. 30, 2022 |
|
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
| Increase in fair value of warrant liabilities | $ 1.2 | $ 0.0 | $ 37.6 | $ 0.0 | $ 0.0 | |
| Impairment loss on business held for sale | $ 0.0 | $ 0.0 | 3.5 | $ 0.0 | $ 0.0 | |
| Disposal Group, Held-for-sale, Not Discontinued Operations | Biodex Rehabilitation Business | ||||||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
| Disposal group, including discontinued operation, consideration | $ 8.0 | |||||
| Impairment loss on business held for sale | $ 3.5 | |||||
| X | ||||||||||
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|